2024-08-28T13:01:03-07:00 2023-12-31 Crosby & Kaneda CPAs LLP 548 Market St PMB 97503 San Francisco CA 94104 990 2023-01-01 680087234 Scleroderma Research Foundation SCLE 4158349444 220 Montgomery St Ste 484 San Francisco CA 94104 Joanne Gold Executive Dir. 2024-08-28 true true Felix Gorrindo P01658413 5108352727 2023 2024-08-08 14:25:15Z Luke Evnin PhD 220 Montgomery St Ste 484 San Francisco CA 94104 8770386 false X www.srfcure.org X 1987 CA The SRF is laser-focused on finding a cure for scleroderma by raising critical funds for research investments, fostering collaboration among the worlds top scientists and institutions to drive innovation, and raising awareness about this rare disease. 11 10 9 365 0 5376802 3932952 170531 3832233 116754 904546 228651 -251693 5892738 8418038 2442093 2482921 0 675017 891428 0 395928 1541492 3113250 4658602 6487599 1234136 1930439 11143637 18654748 1240870 7122391 9902767 11532357 X The mission of the Scleroderma Research Foundation is to fund and facilitate the most promising, highest quality research aimed at new treatments and, ultimately, a cure for scleroderma true true 3547920 2482921 The SRF Research Program: Led by a Scientific Advisory Board comprised of some of the most highly regarded scientists in the nation, the SRFs research program actively seeks out and recruits experts from the fields of rheumatology, immunology, genetics, and fibrosis, as well as, experts in cutting-edge technologies to join the scleroderma research community. With an intense focus on identifying projects and investigators likely to move scleroderma research forward, the SRF funds a diverse portfolio of projects led by top-tier investigators. 1513167 3832233 CONQUEST is a global, perpetual, clinical trial platform developed by the SRF in coordination with partner biopharmaceutical companies to accelerate the clinical development of agents for scleroderma. CONQUEST is designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from phase 2b to phase 3 clinical trials. CONQUEST will make an enduring contribution to the scleroderma community by creating an ecosystem designed to enable rapid and efficient development of novel drugs for scleroderma patients. 553858 SRF Education & Awareness Program: Many patients hear the word scleroderma for the first time when they are diagnosed. We strive to raise awareness and provide educational resources because lack of awareness about scleroderma often causes delays in treatment or misdiagnosis. As an innovator in scleroderma research, the SRF is uniquely qualified to provide those living with this disease, the medical community, and the general public with the most up-to-date, trusted and relevant news and information about complications, treatments, and related research through our website, webinars, annual patient forum, and monthly eNewsletter. And we deliver stories of impact that connect and inspire patients, as well as address issues related to diversity, equity, and inclusion that patients may encounter as they navigate diagnosis, treatment, and living with the disease. 5614945 true true false false false false false false false false true false false false true true true false false false false false false false true false false true false true false false false false false false false false true false false false false false false false false true 26 0 true 9 true false false false false false true true false 0 false false false false false false false X 11 10 true false false false false false true false false false false true true true true true true true true false CA X X X Cindy Young 4158349444 220 Montgomery St Ste 484 San Francisco CA 94104 Joanne Gold Executive Dir. 40.00 0.00 X X 203286 0 3214 Kate Ceredona Dir Philanthropy 40.00 0.00 152315 0 6516 Gloria Blecha Sr Dir Comm O & Ed 40.00 0.00 129705 0 11123 Hannah Young Dir Communications 40.00 0.00 110376 0 5867 Luke Evnin PhD Chairman 30.00 0.00 X X 0 0 0 Deann Wright Secretary 10.00 0.00 X X 0 0 0 Susan Feniger Treasurer 10.00 0.00 X X 0 0 0 Omar Baker MD Board Member 2.00 0.00 X 0 0 0 Sharon Dobie MD Board Member 2.00 0.00 X 0 0 0 Eric Kau MD Board Member 2.00 0.00 X 0 0 0 David Knoller Board Member 1.00 0.00 X 0 0 0 Violetta Merin Board Member 2.00 0.00 X 0 0 0 Caryn Zucker Board Member 1.00 0.00 X 0 0 0 Regina Hall Board Member 2.00 0.00 X 0 0 0 Jeff Seaman Board Member 2.00 0.00 X 0 0 0 595682 26720 4 false true false Kelly Oliver 838 61st St Oakland CA 94608 CONQUEST consultant 359375 Wade Benton 870 Crestview Dr San Carlos CA 94070 CONQUEST consultant 310000 Dahlia Garza 6 Giles Hill Rd Redding CT 06896 CONQUEST consultant 230517 Ravix Financial Inc 226 Airport Pkwy Ste 400 San Jose CA 95110 Finance & human resources 200121 BrowneMusser 10 Rice Ln Larkspur CA 94939 Mktg, adv, outreach 121376 7 26279 1141288 2765385 423912 3932952 Clinical trial platform 900099 3832233 3832233 3832233 904546 904546 0 0 0 0 93400 1141288 352348 -258948 0 0 Other income 900099 7255 7255 7255 8418038 3832233 911801 X 2482921 2482921 0 0 0 204561 122737 61368 20456 0 592227 369514 62340 160373 0 37801 21632 6282 9887 56839 35145 8503 13191 0 298892 298892 236971 236971 0 0 40277 40277 1831562 1784379 24664 22519 182044 140141 8546 33357 93632 44929 7669 41034 98241 39390 8662 50189 0 84773 50864 8477 25432 17412 4559 584 12269 0 207214 206501 162 551 0 0 13978 8388 1396 4194 8254 4953 825 2476 0 6487599 5614945 476726 395928 1489493 3921428 174 12296 1207075 1071849 0 0 0 0 0 38910 56574 88950 57321 45607 31629 8215407 13488695 0 0 0 146971 72277 11143637 18654748 775777 2842768 20000 287435 300849 157658 3978774 1240870 7122391 X 8984292 11531310 918475 1047 9902767 11532357 11143637 18654748 1930439 -300849 X false true X true false X 2892050 3743217 3549644 5376802 3932952 19494665 0 0 2892050 3743217 3549644 5376802 3932952 19494665 5581189 13913476 74912 347227 98683 116754 309318 946894 0 16529 7255 23784 20465343 4017764 0.67990 0.60050 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 88950 57321 31629 31629 Due to partners 3900440 Operating lease liability 78334 3978774 X 8377761 8377761 40277 40277 8418038 6447322 6447322 40277 40277 6487599 Part X : FIN48 Footnote The Internal Revenue Service and the California Franchise Tax Board have determined that the Organization is exempt from federal and state income taxes under IRC 501(c)(3) and California RTC 23701(d). The Organization has evaluated its current tax positions as of December 31, 2023 and is not aware of any significant uncertain tax positions for which a reserve would be necessary. The Organizations tax returns are generally subject to examination by federal and state taxing authorities for three and four years, respectively, after they are filed. false Cool Comedy 1234688 1141288 93400 87336 115072 149940 1234688 1141288 93400 87336 115072 149940 352348 -258948 true Boston Childrens Hospital Co 410 Park Dr Ste 602 Boston MA 02215 042774441 501c3 15000 0 Research Columbia University PO Box 29789 Gen Post Office New York NY 10087 135598093 501c3 23936 0 Research Duke University PO Box 602651 Charlotte NC 28260 560532129 501c3 23794 0 Research Georgetown Univ Medical Ctr PO Box 571164 Washington DC 20057 522218584 501c3 35194 0 Research Hospital for Special Surgery 535 E 70th St New York NY 10021 131624135 501c3 168444 0 Research John Hopkins University 12529 Collections Center Dr Chicago IL 60693 520595110 501c3 135090 0 Research Massachusetts GeneralHospital 55 Fruit St YAW2C Boston MA 02114 042697983 501c3 19135 0 Research Mayo Clinic PO Box 860334 Minneapolis MN 55486 416011702 501c3 24338 0 Research Medical Univ of SouthCarolina 19 Hagood Ave Ste 805 MSC 804 Charleston SC 29425 576028985 501c3 7653 0 Research Northwestern University 633 N St Clair 18-041 Chicago IL 60611 362167817 501c3 45866 0 Research NYU Grossman School Medicine 435 30th St 8th Fl New York NY 10016 135562309 Gov 100000 0 Research Regents of UCLA 1125 Murphy Hall Los Angeles CA 90095 956006143 501c3 19757 0 Research Regents of Univ of CA-UCSF PO Box 748872 Loa Angeles CA 90074 946036493 501c3 42320 0 Research Regents of Univ of Michigan Box 223131 Pittsburgh PA 15251 386006309 501c3 67153 0 Research Stanford School of Medicine PO Box 44253 San Francisco CA 94144 941156365 501c3 673018 0 Research Trustees of Dartmouth College 11 Rope Ferry Rd Ste 6210 Hanover NH 03755 020222111 501c3 117950 0 Research Trustees of the Univ of PA PO Box 785541 Philadelphia PA 19178 231352685 501c3 79935 0 Research Univ of TX Health Science Ctr PO Box 301418 Dallas TX 75303 741761309 501c3 265286 0 Research University of Pittsburgh 3100 Cathedral of Learning Pittsburgh PA 15260 250965591 501c3 75000 0 Research University of Utah PO Box 581374 Salt Lake City UT 84158 876000525 501c3 279048 0 Research Vanderbilt University Med Ctr PO Box 121236 Dallas TX 75312 352528741 501c3 140004 0 Research Yale University PO Box 208011 TAC 5669 New Haven CT 06520 060646973 501c3 125000 0 Research 22 0 Grantmaker's Description of How Grants are Used As part of the extensive continuing grant application process, grantees are required to provide a summary accounting of the grant from the prior funding year along with any remaining balances. This information, along with the proposed budget for the next funding cycle is reviewed by our Scientific Advisory Board (SAB) during the annual scientific workshop. The Board of Directors meets to discuss the SAB recommendations and funding decisions are agreed upon. X X false false false false false false false false false Joanne Gold Executive Dir. 184786 18500 3214 206500 Kate Ceredona Dir Philanthropy 148315 4000 6516 158831 X 13 352080 FMV X Auction items 4 71832 FMV false false false Part I, Line 33, Revenues Not Reported The Organization received a stock donation of 486,800 for a contribution receivable recognized in 2022. Form 990, Part III, Line 2 In August 2023, The SRF launched CONQUEST, a highly innovative clinical trial platform designed to rapidly advance promising treatments for scleroderma and to identify those agents that should progress from Phase 2b to Phase 3 clinical trials. Using a model first created over a decade ago to accelerate oncology drug development, the SRF platform is the first of its kind in rare autoimmune diseases. In its initial iteration, CONQUEST will focus on Interstitial Lung Disease secondary to Scleroderma (SSc-ILD). In the future, the platform will be expanded to address other manifestations of scleroderma. Form 990, Part VI, Section A, Line 1a A separate Finance Committee reviews monthly financial performance and previews audit and tax returns prior to full Board review. Form 990, Part VI, Section A, Line 2 Luke Evnin (Chairman) is married to Deann Wright (Secretary). Form 990, Part VI, Section B, Line 11b A draft will be sent to the Finance Committee and once it clears their review, it will go to the full Board for approval. Form 990, Part VI, Section B, Line 12c Conflict of interest policy is discussed with all BOD members in annual review of Bylaws, members are asked to disclose any updates or changes that may conflict with the stated policy. Form 990, Part VI, Section B, Line 15a Market comparisons were done during initial recruitment, Recommendations for bonus/salary increases were based on industry standards and discussed/voted on during an executive session of the February 2024 BOD meeting Form 990, Part VI, Section B, Line 15b Process included review of publicly available compensation data, discussions with BOD to set salary max and bonus allowances as part of annual budgeting. If there is a request to exceed budgeted salary, BOD approval is required by vote. Form 990, Part VI, Section C, Line 19 Financial statements, bylaws, and conflict of interest policy are available upon request 990 Part IX, Statement of Functional Expenses In addition to the activity reflected in the financial statements, the Organization launched a platform clinical trial in 2023. As part of the launch, the Organization became responsible for significant clinical trial costs. Under agreements with external partnering corporations, the Organization receives funds in advance to be paid for clinical trial costs. The Organization reports such funds as Due to Clinical Trial. $25,460,149 in funds received and disbursed were related to this platform clinical trial; they were accounted for on a pass-through basis during the year ended December 31, 2023.